Severibuxine is primarily used in the development of targeted cancer therapies, particularly in the inhibition of specific kinases involved in tumor growth and proliferation. It has shown promising activity in clinical trials for treating non-small cell lung cancer and melanoma by blocking abnormal signaling pathways in cancer cells. Its high selectivity allows for reduced damage to healthy cells, improving patient tolerance during treatment. Additionally, severibuxine is being investigated for use in combination therapies to overcome drug resistance in advanced cancers. Ongoing research explores its potential in inflammatory diseases due to its modulatory effects on cellular immune responses.